natgillin/translations-raw huggingface dataset:
0.5 g 1 g
0,5 g
0.5 g x 12 sachets
0,5 g x 12 vrećica
0.5 mg + Laser n=118
Ranibizumab 0,5 mg + laser n=118
0.5 mg + laser n=83
Prethodni ranibizumab 0,5 mg + laser n=83
0.5 mg alone n=125
LIP samo ranibizumab 0,5 mg
0.5 mg and 1 mg Tablets Cellulose, Microcrystalline
0,5 mg i 1 mg tablete celuloza, mikrokristalična
0.5 mg ethyl hydroxybenzoate (as the sodium salt) and sucrose (trace).
0,5 mg etilhidroksibenzoata (u obliku natrijeve soli) i saharozu (u tragovima).
0.5 mg every 48 hours
0,5 mg svakih 48 sati
0.5 mg every 5-7 days
0,5 mg svakih 5-7 dana
0.5 mg every 72 hours
0,5 mg svaka 72 sata
0.5 mg single dose
0,5 mg jednokratna
0.5 mg single dose
0,5 mg jednokratna doza
0.5 mg single dose
pojedinačna doza od 0,5 mg
0.5 mg tablet: white, round, biconvex tablets of 6 mm, marked with the Bayer cross on one side and 0.5 and an “R” on the other side.
0,5 mg tableta: bijele, okrugle, bikonveksne tablete od 6 mm, označene Bayerovim križem s jedne strane te brojem 0.5 i slovom “R” s druge strane.
0.5 mg tablets are white, 1 mg tablets are yellow and 2 mg tablets are peach-coloured.
Tablete od 0,5 mg su bijele boje, tablete od 1 mg su žute, a tablete od 2 mg boje breskve.
0.5 mg twice daily
0,5 mg dvaput na dan
0.5 mg “disease activity” (n=116)
„aktivnost bolesti“ (n=116)
0.5 mg “vision stability” (n=105)
„stabilnost vida“ (n=105)
0.5 mg/kg weekly
0,5 mg/kg tjedno
0.5 mg/kg/day asfotase alfa group (5 evaluable patients): mean (SD) mineralisation lag-time was 257 (146) days at baseline and 130 (142) days at week 48
48. tjednu skupina koja je primala 0,5 mg/kg asfotaze alfa na dan (5 procjenjivih bolesnika): prosječno (SD) vrijeme do mineralizacije bilo je 257 (146) dana na početku i 130 (142) dana u 48. tjednu.
0.5 mg/kg/week) should not be exceeded as there is limited experience with higher doses in this patient group.
0,5 mg/kg/tjedan) jer je iskustvo s višim dozama u ove skupine bolesnika ograničeno.
0.5 mg/ml dexmedetomidine hydrochloride
0,5 mg/ml deksmedetomidin hidroklorida
0.5 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after administration of the injection.
0,5 mg/ml peroralna suspenzija mogu se koristiti za nastavak liječenja u dozi 0,1 mg meloksikama/kg tjelesne mase, 24 sata nakon primjene injekcije.
0.5 mL
0,75 ml
0.5 ml
40000 IU/1 ml
0.5 mL (0.5 mg/mL) 1 pre-filled syringe
0,5 ml (0,5 mg/ml) 1 napunjena
0.5 mL (10 million IU/mL)
0,5 ml (6 milijuna IU/ml)
0.5 ml (10 µ/ml)
0,5 ml (10 µg/ml)
0.5 ml (10000 IU)
0.5 ml (10000 IU/ml)
0.5 ml (10000 IU/ml)
EU/1/07/431/047
0.5 ml (40000 IU/ml) 1 pre-filled syringe
napunjenih štrcaljki
0.5 ml (40000 IU/ml) 4 pre-filled syringes
napunjenih štrcaljki
0.5 ml (Fill 0.61 ml)
0,5 ml (Punjenje 0,61 ml)
0.5 ml 1 pre-filled syringe (Luer Lock) + 1 needle
(Luer Lock) + 1 igla
0.5 ml 2 x 10 pre-filled syringes (Luer Cone) + 20 needles
2 x 10 štrcaljka s uloškom
0.5 ml concentrate for solution for infusion in a pre-filled syringe (type I glass, siliconised) with plunger stopper (bromobutyl rubber) and luer lock system (polypropylene siliconised and polycarbonate) with tip cap (styrene butadiene rubber) with a cannula; pack size of 1.
0,5 ml koncentrata za otopinu za infuziju u napunjenoj štrcaljki (staklo tip I, silikonizirano) s čepom klipa (bromobutil guma) i luer lock sustavom (silikonizirani polipropilen i polikarbonat) sa zatvaračem vrha (stiren butadien guma) s cjevčicom; veličina pakiranja: 1.
0.5 ml dose contains:
Doza od 0,5 ml sadrži:
0.5 ml N=628
0,5 ml N=628
0.5 ml of solution for injection in 1.5 ml cartridge (type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a rubber inlay.
0,5 ml otopine za injekciju u ulošku od 1,5 ml (staklo tip I), s čepom klipa (halobutilna guma) i aluminijskim sigurnosnim zatvaračem s gumenim uloškom.
0.5 mL of solution in a pre-filled syringe (type I glass) with a plunger stopper (halobutyl rubber) and plunger (plastic), and with a needle for injection (stainless) – pack of 1.
0,5 ml otopine u napunjenoj štrcaljki (staklo tip I) s čepom klipa (halobutilna guma) i klipom (plastičnim) te s iglom za injiciranje (nehrđajućom) – pakiranje s 1 štrcaljkom.
0.5 ml of solvent in pre-filled syringe (glass) and plungers (plastic) for assembly with the pre-filled syringe.
Otapalo 0,5 ml u napunjenoj štrcaljki (staklo) i klipovi (plastika) za sastavljanje napunjene štrcaljke.
0.5 ml of suspension in a pre-filled syringe (type I glass) with plunger stoppers (butyl).
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tip I) s čepom klipa (butil).
0.5 ml of suspension in a prefilled syringe (type I glass) with a plunger stopper (rubber butyl).
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tip I) sa čepom klipa (butil guma).
0.5 ml of suspension in a vial (type I glass) for 1 dose with a stopper (rubber butyl).
0,5 ml suspenzije u bočici (staklo tip I) za 1 dozu sa čepom (butilna guma).
0.5 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl).
0,5 ml suspenzije u bočici (staklo tip I) sa čepom klipa (butil guma).
0.5 ml of suspension in a vial (type I glass) with a stopper (butyl).
0,5 ml suspenzije u bočici (staklo tip I) s čepom (butil).
0.5 ml of suspension in pre-filled syringe (type I glass) with a plunger stopper (rubber butyl) with or without separate needle in a pack size of 1, or without needles in a pack size of 10.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tipa I) sa zatvaračem (butil guma) sa ili bez dodatne igle u pakiranju po 1, ili bez igala u veličini pakiranja od 10 komada.
0.5 ml solution for injection (40 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,5 ml otopine za injekciju (40 µg/ml darbepoetina alfa) u napunjenoj brizgalici sa štrcaljkom od stakla tipa 1 i iglom od 27 gauge od nehrđajućeg čelika.
0.5 ml solution for injection (40 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,5 ml otopine za injekciju (40 μg/ml darbepoetina alfa) u napunjenojštrcaljki od stakla tip 1 s iglom od 27 gauge od nehrđajućeg čelika.
0.5 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
0,5 ml otopine za injekciju u napunjenoj štrcaljki, staklo tipa I, s pričvršćenom čeličnom iglom za injiciranje i gumenim čepom obloženim politetrafluoroetilenom (PTFE-om).
0.5 mL solution in a pre-filled syringe (Type 1 glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex) in a pre-filled syringe.
0,5 ml otopine u napunjenoj štrcaljki (staklo tipa 1) s pričvršćenom iglom (od nehrđajućeg čelika) i pokrovom za iglu (od gume koja sadrži lateks) u napunjenoj brizgalici.
0.5 ml solution in a pre-filled syringe (type I glass) with a tip cap (bromobutyl rubber), a plunger stopper (teflonised chlorobutyl rubber) and an injection needle (stainless steel) or an injection needle (stainless steel) with a safety shield (safety needle) or an injection needle (stainless steel) with a safety device.
0,5 ml otopine u napunjenoj štrcaljki (staklo tip I) sa zatvaračem vrha (bromobutil guma), čepom klipa (teflonizirana klorobutil guma) i injekcijskom iglom (nehrđajući čelik) ili injekcijskom iglom (nehrđajući čelik) sa sigurnosnim štitnikom (sigurnosna igla) ili injekcijskom iglom (nehrđajući čelik) sa sigurnosnom napravom.
0.5 mL solution in a type I glass 1 mL syringe with a fixed stainless steel needle and a needle cover containing dry natural rubber (a derivative of latex).
0,5 ml otopine u štrcaljki od 1 ml, izrađenoj od stakla tipa I, s pričvršćenom iglom od nehrđajućeg čelika i pokrovom igle koji sadrži suhu prirodnu gumu (derivat lateksa).
0.5 mL solution in a type I glass 2 mL vial closed with a coated butyl rubber stopper.
0,5 ml otopine u bočici od 2 ml, izrađenoj od stakla tipa I i zatvorenoj obloženim čepom od butilne gume.
0.5 mL solution is sufficient for a single dose (see section 6.6).
0,5 mL otopine dovoljno je za jednu dozu (vidjeti dio 6.6).
0.5 ml suspension for injection in pre-filled syringe (Type I glass) with a plunger rod (polypropylene), a plunger stopper (latex free grey butyl rubber) and a protective-tip cap (latex free grey butyl rubber) -
0,5 ml suspenzije za injekciju u napunjenoj štrcaljki (staklo tipa I) s klipom (polipropilen), čepom klipa (siva butilna guma koja ne sadrži lateks) i zaštitnom kapicom (siva butilna guma koja ne sadrži lateks).
0.5 ml suspension in a pre-filled syringe (glass) with plunger stopper (siliconized FluroTec-laminated bromobutyl elastomer) and a tip cap (synthetic isoprene-bromobutyl blend) with two needles in pack size of 1 or 10.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo) s čepom na klipu (silikonizirani bromobutilni elastomer obložen FluroTecom ) i zatvaračem na vrhu (mješavima sintetičkog izopren-bromobutila) s dvije igle u pakiranju od 1 ili 10 napunjenih štrcaljki.
0.5 ml suspension in a pre-filled syringe (Type I glass) with a plunger stopper (Type I bromobutyl rubber) and with a protective tip cap (Type I or Type II rubber) with or without needles.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tipa I) s čepom klipa (bromobutilna guma tip I) i zaštitnim zatvaračem vrha (guma tipa I ili tipa II) sa ili bez igala.
0.5 ml suspension in a pre-filled syringe (type I glass) with a stopper (butyl rubber) with or without needles.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tip I) s čepom (butil guma), sa ili bez igala.
0.5 ml suspension in a vial (glass) with stopper (FluroTec-coated or Teflon-coated chlorobutyl elastomer) and flip-off plastic cap (aluminium crimp band) in a pack size of 1, 10 or 20.
0,5 ml suspenzije u bočici (staklo) s čepom (klorobutil elastomer obložen FluroTecom ili Teflonom) i plastičnim „flip-off“ zatvaračem (s aluminijskim prstenom) u pakiranjima od 1, 10 ili 20 bočica.
0.5 ml suspension in a vial (type I glass) with a stopper (butyl rubber).
0,5 ml suspenzije u bočici (staklo tip I) s čepom (butil guma).
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), with 1 separate needle – pack size of 1 or 10.
0,5 ml suspenzije u napunjenoj štrcaljki (staklenoj, tip I) s čepom klipa (butil) i zatvaračem vrha (butil), s 1 zasebnom iglom - veličina pakiranja 1 ili 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), with 2 separate needles – pack size of 1 or 10.
0,5 ml suspenzije u napunjenoj štrcaljki (staklenoj, tip I) s čepom klipa (butil) i zatvaračem vrha (butil), s 2 zasebne igle - veličina pakiranja 1 ili 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), without needle – multipack of 5 packs of 10.
0,5 ml suspenzije u napunjenoj štrcaljki (staklenoj, tip I) s čepom klipa (butil) i zatvaračem vrha (butil), bez igle – višestruko pakiranje s 5 pakiranja od po 10 komada.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), without needle – pack size of 1 or 10.
0,5 ml suspenzije u napunjenoj štrcaljki (staklenoj, tip I) s čepom klipa (butil) i zatvaračem vrha (butil), bez igle – veličina pakiranja 1 ili 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (halobutyl) and tip cap (halobutyl), with 1 separate needle.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tip I) s čepom klipa (halobutil) i zatvaračem vrha (halobutil), s 1 zasebnom iglom.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (halobutyl) and tip cap (halobutyl), with 2 separate needles.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tip I) s čepom klipa (halobutil) i zatvaračem vrha (halobutil), s 2 zasebne igle.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (halobutyl) and tip cap (halobutyl), without needle.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo tip I) s čepom klipa (halobutil) i zatvaračem vrha (halobutil), bez igle.
0.5 ml) doses or two half adult (i.e.
0,5 ml) ili dvije polovice doze za odrasle (tj.
0.5 mL.
0,5 ml
0.5 mU/L. In those patients with a normal TSH at baseline, elevation of TSH level above 0.5 mU/L was observed post baseline in 57% of lenvatinib-treated patients as compared with 14% of placebo-treated patients.
U tih bolesnika s normalnim TSH-om na početku, povišenje razine TSH-a iznad 0,5 mU/l opaženo je poslije početka ispitivanja u 57% bolesnika liječenih lenvatinibom u usporedbi s 14% bolesnika liječenih placebom.
0.5 or 1 ml injection syringes (with scale intervals of 0.02 ml or smaller).
Injekcijske štrcaljke od 0.5 ili 1 ml (mjerna ljestvica s razmacima od 0,02 ml ili manje).
0.5 x 19 mm, 25 G x ¾’’),
0,5 x 19 mm, 25 G x ¾’’),
0.5 µg/kg
0,5 µg/kg
0.5 g/kg
0,5 µg/kg
0.5%), abdominal distension (0.7% vs 1.0%), dry mouth (0.3% vs 0%), retching (0.2% vs 0%)
prema 1,0%), suha usta (0,3% prema 0%), dizanje želuca (0,2% prema 0%)
0.5)
vrijednosti
0.50 – 0.83 p=0.0007
0,50 – 0,83 p=0,0007
0.51 (0.41, 0.62), p<0.0001
0,51 (0,41; 0,62); p<0,0001
0.51 (95% CI: 0.39, 0.67) for BRAF wild type and 0.74 (95% CI: 0.46, 1.18) for BRAF mutant with prior BRAF treatment.
0,51 (95% CI: 0,39; 0,67) za bolesnike s divljim tipom gena BRAF i 0,74 (95% CI: 0,46; 1,18) za bolesnike s mutacijom u genu BRAF koji su prethodno primali BRAF terapiju.
0.518 (p-value  0.0001)
0,518 (p-vrijednost < 0,0001)
0.52 and 0.67.
0,52 i 0,67.
0.53
ritonavirom.
0.55 mM
0,55 mM
0.56 – 0.93 p=0.0114
0,56 – 0,93 p=0,0114
0.57 – 0.95 p=0.020
0,57 – 0,95 p=0,020
0.57, (95% CI: 0.40,
0,57, (95% CI: 0,40;
0.58 (0.38, 0.87) (p=0.0084)
0,58 (0,38, 0,87) (p=0,0084)
0.58 (0.45, 0.74), p<0.0001
0,58 (0,45; 0,74); p<0,0001
0.58 x 109/L and absolute reticulocyte count was 24.3 x109/L. Eighty-six percent of patients were RBC transfusion dependent, and 91% were platelet transfusion dependent.
Osamdeset šest posto bolesnika bilo je ovisno o transfuziji eritrocita, a 91% je bilo ovisno o transfuziji trombocita.
0.59
Gradus 3
0.6 %
(n=635) 0,6
0.6 mg liraglutide) and 16 units, respectively, and the dose was titrated twice weekly according to Table 2.
Doza je titrirana dvaput tjedno prema Tablici 2.
0.6 mg/kg as 15-minute infusions at 3-day intervals, six times in total (for a cumulative dose that corresponded to AUC levels about 6 times the human therapeutic exposure) while five 15-minute infusions of 0.25 mg/kg administered at 2–3-week intervals (a cumulative dose that corresponded to 7 times the human therapeutic exposure) were well tolerated in dogs.
U ispitivanjima s intravenskom infuzijom bubrežna podnošljivost zoledronatne kiseline utvrđena je u štakora koji su dobivali 0,6 mg/kg u obliku 15-minutne infuzije u intervalima od tri dana, ukupno šest puta (čime se dobila kumulativna doza koja je odgovarala AUC razinama koje su bile otprilike šesterostruko veće od terapijske izloženosti u ljudi), dok su psi dobro podnosili pet 15-minutnih infuzija u dozi od 0,25 mg/kg koje su primjenjivane u intervalima od 2-3 tjedna (kumulativna doza je odgovarala sedmerostrukoj terapijskoj izloženosti u ljudi).
0.6 ml (16667 IU/ml)
0,6 ml (16667 IU/ml)
0.6 ml (3333 IU/ml) 1 pre-filled syringe
0,6 ml (3333 IU/ml)
0.6 ml (3333 IU/ml) 6 pre-filled syringes
0,6 ml (3333 IU/ml)
0.6 ml (33333 IU/ml)
0,6 ml (33333 IU/ml)
0.6 ml (50000 IU/ml)
0,6 ml (50000 IU/ml)
0.6 ml (600
0,6 ml (600 μg/ml)
0.6 mL in a 1 mL graduated syringe for Somatropin Biopartners 4 mg
0,6 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 4 mg
0.6 mL of solution (12 mg methylnaltrexone bromide)
0,6 ml otopine (12 mg metilnaltreksonbromida)
0.6 mL of solution in a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and an orange polypropylene plunger rod.
0,6 ml otopine u graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, s iglom sa štitnikom koja se ne može odvojiti, zatvorenoj čepom od klorbutil-gume i narančastim klipom od polipropilena.
0.6 ml of solution in a pre-filled syringe (type I glass) with a plunger stopper
0,6 ml otopine u napunjenoj štrcaljki (staklo tipa I) s čepom klipa
0.6 ml solution for injection (500 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,6 ml otopine za injekciju (500 µg/ml darbepoetina alfa) u napunjenoj brizgalici sa štrcaljkom od stakla tipa 1 i iglom od 27 gauge od nehrđajućeg čelika.
0.6 ml solution for injection (500 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,6 ml otopine za injekciju (500 μg/ml darbepoetina alfa) u napunjenšotrjcaljki od stakla tipa 1 s iglom od 27 gauge od nehrđajućeg čelika.
0.6 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
0,6 ml otopine za injekciju u napunjenoj štrcaljki, staklo tipa I, s pričvršćenom čeličnom iglom za injiciranje i gumenim čepom obloženim politetrafluoroetilenom (PTFE-om).
0.6 mmol (or 14 mg) sodium per vial.
0,6 mmol (ili 14 mg) natrija po bočici.
0.61 (0.25, 1.48) (a)
0,61 (0,25; 1,48) (a)
0.61 μg/mL to 0.76 μg/mL for 90 mg ustekinumab every 8 weeks or every 12 weeks respectively.
1,97 μg/ml do 2,24 μg/ml i od 0,61 μg/ml do 0,76 μg/ml za 90 mg ustekinumaba svakih 8 tjedana odnosno svakih 12 tjedana.
0.62 (0.49, 0.77) (w)
0,62 (0,49; 0,77) (w)
0.625 mL
0,625 mL
0.63
paritaprevir
0.63 U/kg
0,63 U/kg
0.63); p < 0.0001], and other types of bleeding (Table 6).
(95% CI): 0,47 (0,34, 0,63); p < 0,0001] i drugih vrsta krvarenja (tablica 6).
0.65 (0.44, 0.96)
0,65 (0,44; 0,96) p=0,0275
0.65 ml solution for injection (200 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,65 ml otopine za injekciju (200 µg/ml darbepoetina alfa) u napunjenoj brizgalici sa štrcaljkom od stakla tipa 1 i iglom od 27 gauge od nehrđajućeg čelika.
0.65 ml solution for injection (200 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,65 ml otopine za injekciju (200 μg/ml darbepoetina alfa) u napunjenšotjrcaljki od stakla tipa 1 s iglom od 27 gauge od nehrđajućeg čelika.
0.65 mM
0,65 mM
0.66 (0.51, 0.86) p = 0.002**
0,66 (0,51,0,86) p = 0,002
0.66 [0.54, 0.81] (p-value5 <0.0001)
0,66 [0,54; 0,81] (p-vrijednost5 <0,0001)
0.660 (p-value = 0.00004)
0,660 (p-vrijednost = 0,00004)
0.661 (0.512 to 0.852)
0,797 (0,679 do 0,936)
0.667 ml/10 kg bodyweight).
0,667 ml/10 kg tjelesne mase).
0.67 (0.41 – 1.10) p=0.1116
0,67 (0,41 – 1,10) p=0,1116
0.67 (0.48–0.96)
(N=153)
0.67 (0.48–0.96)
Drugi oblici
0.67 (0.48–0.96)
Karcinom
0.67 µg/ml, and 0.65 µg/ml, respectively, indicating no systemic accumulation of aztreonam following 3 times a day dosing.
75 mg 3 puta na dan iznosile su 0,55 µg/ml, 0,67 µg/ml i 0,65 µg/ml, što ne ukazuje ni na kakvu sistemsku akumulaciju aztreonama kod doziranja 3 puta na dan.
0.68
NP
0.68
UGT1A1
0.68 (0.53, 0.87) p = 0.002**
0,68 (0,53,0,87) p = 0,002
0.68 (0.59, 0.78) (p-value < 0.0001)
0,68 (0,59; 0,78) (p-vrijednost < 0,0001)
0.7 mg/kg once daily
0,7 mg/kg jedanput na dan
0.7 ml (100 μg/0.5 ml)
0,7 ml (100 μg/0,5ml)
0.7 mL in a 1 mL graduated syringe for Somatropin Biopartners 10 mg
0,7 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 10 mg
0.7*
mučnina
0.70 (0.40, 1.23) (p=0.22)
0,70 (0,40, 1,23) (p=0,22)
0.70 (0.51, 0.97) p = 0.033**
0,70 (0,51, 0,97) p = 0,033
0.70 (0.57, 0.87) (w)
0,70 (0,57; 0,87) (w)
0.70 (1 pipette)
0,70 mL (1 pipeta)
0.70 (95% CI: 0.55, 0.90) (p-value = 0.0050e)
0,70 (95% CI: 0,55, 0,90) (p-vrijednost = 0,0050e)
0.705 - 0.971; p = 0.0203).
0,971; p = 0,0203).
0.71 (0.56-0.89)
escitaloprama.
0.71 points (SD: 2.14; 95% CI: –0.43–1.84)
0,71 boda (SD: 2,14; 95 % CI: -0,43-1,84)
0.72 (0.51, 1.02)
cisplatin+paklitaksel
0.72 ml (Fill: 0.88 ml)
0,72 ml (Punjenje: 0,88 ml)
0.72 mL of solution in 1.5 mL cartridge (type I glass) with a grey rubber piston and an aluminium crimp-cap with a rubber inlay.
0,72 ml otopine u ulošku volumena 1,5 ml (staklo tipa I ) sa sivim gumenim klipom i aluminijskim zatvaračem s gumenim umetkom.
0.73
opservacije
0.73
paritaprevir
0.74 [0.58, 0.94] (p-value5 = 0.0132)
0,74 [0,58; 0,94] (p-vrijednost5 = 0,0132)
0.75 (0.44, 1.29) (a)
0,75 (0,44; 1,29) (a)
0.75 (0.55, 1.01)
topotekan+paklitaksel
0.75 g/0.1875 g
0,75 g/0,1875 g
0.75 mg torasemide 3 mg torasemide 7.5 mg torasemide
0,75 mg torasemida 3 mg torasemida 7,5 mg torasemida
0.75 mg/kg body weight as an intravenous injection, followed immediately by an infusion (drip) into vein of 1.75 mg/kg body weight, per hour for at least the duration of the PCI.
0,75 mg/kg tjelesne težine kao injekcija u venu, nakon čega odmah slijedi infuzija (drip) u venu od 1,75 mg/kg tjelesne težine na sat barem tijekom trajanja PCI-ja.
0.75 mg/kg subcutaneously twice daily without initial bolus.
0,75 mg/kg supkutano dva puta na dan bez inicijalnog bolusa.
0.75 mg/m2 dx3 q21
0,75 mg/m2 3 dana svakih 21 dan
0.75 mg/m2 dx3 q21
vakih 2l dan
0.75 micrograms once every two weeks, or
0,75 mikrograma jednom svaka dva tjedna, ili
0.75 ml
0,75 ml (40000 IU/ml)
0.75 ml
30000 IU/0,75 ml
0.75 ml (40000
(Zaštićeno
0.75 ml for the injections at day 13, 15, 17 of therapy.
0,75 ml za injekcije na dane liječenja 13, 15 i 17.
0.75 ml of solution for injection in 1.5 ml cartridge (type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a rubber inlay.
0,75 ml otopine za injekciju u ulošku od 1,5 ml (staklo tip I), s čepom klipa (halobutilna guma) i aluminijskim sigurnosnim zatvaračem s gumenim uloškom.
0.75 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
0,75 ml otopine za injekciju u napunjenoj štrcaljki, staklo tipa I, s pričvršćenom čeličnom iglom za injiciranje i gumenim čepom obloženim politetrafluoroetilenom (PTFE-om).
0.75 mL/pre-filled syringe
0,75 ml/napunjena štrcaljka
0.75 VN.U
0,75 VN.U
0.751 (p-value = 0.0012)
0,751 (p-vrijednost = 0,0012)
0.76
opservacije
0.76 (0.48, 1.21) (a)
0,76 (0,48; 1,21) (a)
0.76 [0.62, 0.94] (p-value5,8 = 0.0126)
0,76 [0,62; 0,94] (p-vrijednost5,8 = 0,0126)
0.760
p-vrije- dnost
0.77 (0.65-0.91)
bez dasabuvira.
0.78 (0.64, 0.94) (w)
0,78 (0,64; 0,94) (w)
0.78h, 95% CI [-1.18, -0.39], p=0.0001. The mean total daily decrease in the OFF time was similar in the entacapone group (-0.80h, 95% CI [-1.20, -0.41], p<0.0001) to that observed in the rasagiline 1 mg group.
Srednje ukupno dnevno smanjenje u OFF vremenu u entakapon skupini (-0,80 h, 95 % CI [-1,20, -0,41], p<0,0001) bilo je slično onom opaženom u razagilin 1 mg skupini.
0.79 (0.59, 1.07)
p  0,1061)
0.79 (0.66-0.94)
pogotovo u slučaju kada se
0.799 (0.715, 0.893)
(N=4212) (N=4187)
0.8
of
0.8
početne
0.8 % (-6.25 %; 8.04 %); P = 0.0028
0,8% (-6,25%; 8,04%); P = 0,0028
0.8 (0.4 – 5.1)d
0,8 (0,4-5,1)d
0.8 - 1 g/kg bw or
0,8 - 1 g/kg TT ili
0.8 - 1 g/kg given on day one; this dose may be repeated once within 3 days
0,8 - 1 g/kg primijenjeno na prvi dan; ta se doza može ponoviti još jednom u iduća 3 dana
0.8 GC
(0,81-1,45)
0.8 mg/kg body weight (BW) of busulfan as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses, followed by cyclophosphamide at 60 mg/kg/day over 2 days initiated for at least 24 hours following the 16th dose of Busilvex (see section 4.5).
0,8 mg/kg tjelesne težine (TT) busulfana u obliku dvosatne infuzije svakih 6 sati tijekom 4 uzastopna dana u ukupno 16 doza, potom slijedi ciklofosfamid u dozi od 60 mg/kg/dan tijekom 2 dana s početkom najmanje 24 sata nakon 16. doze lijeka Busilvex (vidjeti dio 4.5).
0.8 mg/kg body weight (BW) of busulfan as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses, followed by cyclophosphamide at 60 mg/kg/day over 2 days initiated for at least 24 hours following the 16th dose of busulfan (see section 4.5).
0,8 mg/kg tjelesne težine (TT) busulfana u obliku dvosatne infuzije svakih 6 sati tijekom 4 uzastopna dana u ukupno 16 doza, potom slijedi ciklofosfamid u dozi od 60 mg/kg/dan tijekom 2 dana s početkom najmanje 24 sata nakon 16. doze busulfana (vidjeti dio 4.5).
0.8 mg/kg Once Weekly
0,8 mg/kg jednom tjedno